FC
MRVI icon

FORA Capital’s Maravai LifeSciences MRVI Stock Holding History

FORA Capital’s Portfolio MRVI Stock Details MRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-28,539
Closed -$156K – 601
2024
Q4 		$156K Buy
+28,539
New +$184K 0.02% 361
2023
Q1 		– Sell
-13,263
Closed -$190K – 635
2022
Q4 		$190K Buy
+13,263
New +$209K 0.03% 442

Other funds holding MRVI

GL
GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return
1WCM
12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
MFS
Mirabella Financial Services London, United Kingdom $1.06B AUM 19.83% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

FORA Capital's MRVI Position: Q1 2025 in Review

FORA Capital sold out of Maravai LifeSciences (MRVI) in Q1 2025, closing a stake of 28,539 shares — an estimated $156K sold.

FORA Capital first reported a position in MRVI in Q4 2022 and held it in 2 quarters. The position peaked at $190K in Q4 2022. 184 funds tracked by Wall St. Rank hold MRVI as of Q1 2025.

  • FORA Capital reported no remaining Maravai LifeSciences position as of Q1 2025 after selling out during the quarter.
  • FORA Capital sold 28,539 Maravai LifeSciences shares in Q1 2025, an estimated $156K.
  • FORA Capital first reported a position in Maravai LifeSciences in Q4 2022 and held it in 2 quarters.
  • FORA Capital's Maravai LifeSciences position peaked at $190K in Q4 2022.
  • 184 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q1 2025.

Based on FORA Capital's 13F filing for Q1 2025, filed 14 May 2025.